13,140
+4.29%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anterogen Co
Its shares trade on KOSDAQ under the ticker 065660.KQ. It has been listed since 15 February 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩7.54bn and a net loss of ₩1.37bn. At that date it held total assets of ₩88.26bn and shareholders' equity of ₩87.45bn.
Anterogen Co., Ltd. engages in the development and sale of stem cell therapy treatments. The company is headquartered in Seoul, Seoul. The company went IPO on 2016-02-15. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The firm's product portfolio consists of Cupistem which is used for the treatment of Crohn’s fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The firm distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Feb 2016
- Employees
- 39
- Website
- anterogen.com ↗
Leadership
Pay as last reported
- Mi Hyeong KimCo-Chief Executive Officer, Vice President, Director, since 2022
- Seong Gu LeeCo-Chief Executive Officer, Director, since 2022
- Ms, Bang Hui HanManaging Director
- Tae Hui LeeManaging Director, since 2023
- Sun Bae KimInternal Auditor
- Won Dae KimInternal Auditor
- Hong Gi RyuInternal Auditor
- Min Jeong GwakNon-Executive Independent Director
- Chi Jung KimNon-Executive Independent Director
- Ms. Gyeong LeeNon-Executive Independent Director
- Yin Hak LeeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anterogen Co Ltd develops Cupistem for Crohn's fistula treatment using autologous stem cells.
- The company offers stem cell conditioned medias SCM2s for skin function enhancement as cosmetic raw materials.
- Anterogen's Remodullins target pulmonary arterial hypertension treatment with innovative cell therapy.
Weaknesses
- Anterogen's domestic market distribution limits international expansion opportunities.
- The company employs only 39 full-time staff, indicating limited operational capacity.
- Anterogen's IPO in 2016 suggests potential financial constraints for growth.
Opportunities
- Expanding into international markets could increase Anterogen's product reach beyond Korea.
- Growing demand for stem cell therapies presents opportunities for Anterogen's product portfolio.
- Increasing interest in cosmetic applications of stem cell conditioned medias could boost SCM2s sales.
Threats
- Competition from other biotechnology firms in Korea may impact Anterogen's market share.
- Regulatory changes in the Health Care sector could affect Anterogen's product approvals.
- Economic downturns might reduce investment in biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.